Rho-kinase inhibitor targeting the liver prevents ischemia/reperfusion injury in the steatotic

Liver Transplantation

Volumn 21, Issue 1, 2015, Pages 123-131

  Kuroda, Shintaro ^a   Tashiro, Hirotaka ^a   Kimura, Yasuhiro ^b   Hirata, Kaori ^b   Tsutada, Misaki ^b   Mikuriya, Yoshihiro ^a   Kobayashi, Tsuyoshi ^a   Amano, Hironobu ^a   Tanaka, Yuka ^a   Ohdan, Hideki ^a  

^a HIROSHIMA UNIVERSITY   (Japan)

^b HIROSHIMA UNIVERSITY HOSPITAL   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

4 (1 AMINOETHYL) N (4 PYRIDYL)CYCLOHEXANECARBOXAMIDE; ASPARTATE AMINOTRANSFERASE; GREEN FLUORESCENT PROTEIN; LIPOSOME; MYOSIN LIGHT CHAIN; RETINOL; RHO KINASE; AMIDES; LIPOSOMES; PROTEIN KINASE INHIBITORS; PYRIDINES; RHO-ASSOCIATED KINASES; Y 27632;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG TARGETING; ENZYME INHIBITION; FATTY LIVER; HYPOTENSION; IMMUNOHISTOCHEMISTRY; LIPOSOMAL DELIVERY; LIVER BLOOD FLOW; LIVER ISCHEMIA; MALE; MEAN ARTERIAL PRESSURE; NONHUMAN; RAT; REPERFUSION INJURY; STELLATE CELL; SURVIVAL RATE; ANIMALS; ANTAGONISTS AND INHIBITORS; ARTERIAL PRESSURE; BLOOD SUPPLY; CELLS, CULTURED; CHEMICALLY INDUCED; CHEMISTRY, PHARMACEUTICAL; CHOLINE DEFICIENCY; COMPARATIVE STUDY; COMPLICATION; CYTOPROTECTION; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG EFFECTS; ENZYMOLOGY; HEPATIC STELLATE CELLS; LIVER; LIVER CIRCULATION; METABOLISM; PATHOLOGY; PHYSIOPATHOLOGY; PORTAL PRESSURE; RATS, WISTAR; TIME FACTORS;

AMIDES; ANIMALS; ARTERIAL PRESSURE; CELLS, CULTURED; CHEMISTRY, PHARMACEUTICAL; CHOLINE DEFICIENCY; CYTOPROTECTION; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; FATTY LIVER; HEPATIC STELLATE CELLS; HYPOTENSION; LIPOSOMES; LIVER; LIVER CIRCULATION; MALE; PORTAL PRESSURE; PROTEIN KINASE INHIBITORS; PYRIDINES; RATS, WISTAR; REPERFUSION INJURY; RHO-ASSOCIATED KINASES; TIME FACTORS;

EID: 84919644840     PISSN: 15276465     EISSN: 15276473     Source Type: Journal    
DOI: 10.1002/lt.24020     Document Type: Article

References (26)

1. McCormack L, Petrowsky H, Jochum W, Furrer K, Clavien PA. Hepatic steatosis is a risk factor for postoperative complications after major hepatectomy: a matched case-control study. Ann Surg 2007;245:923-930.
2. Gomez D, Malik HZ, Bonney GK, Wong V, Toogood GJ, Lodge JP, Prasad KR. Steatosis predicts postoperative morbidity following hepatic resection for colorectal metastasis. Br J Surg 2007;94:1395-1402.
3. Trevisani F, Colantoni A, Caraceni P, Van Thiel DH. The use of donor fatty liver for liver transplantation: a challenge or a quagmire? J Hepatol 1996;24:114-121.
4. Hui AM, Kawasaki S, Makuuchi M, Nakayama J, Ikegami T, Miyagawa S. Liver injury following normothermic ischemia in steatotic rat liver. Hepatology 1994;20:1287-1293.
5. Caraceni P, Ryu HS, Subbotin V, De Maria N, Colantoni A, Roberts L, et al. Rat hepatocytes isolated from alcoholinduced fatty liver have an increased sensitivity to anoxic injury. Hepatology 1997;25:943-949.
6. Zhang JX, Bauer M, Clemens MG. Vessel- and target cell-specific actions of endothelin-1 and endothelin-3 in rat liver. Am J Physiol 1995;269(pt 1):G269-G277.
7. Hennenberg M, Biecker E, Trebicka J, Jochem K, Zhou Q, Schmidt M, et al. Defective RhoA/Rho-kinase signaling contributes to vascular hypocontractility and vasodilation in cirrhotic rats. Gastroenterology 2006;130:838-854.
8. Trebicka J, Leifeld L, Hennenberg M, Biecker E, Eckhardt A, Fischer N, et al. Hemodynamic effects of urotensin II and its specific receptor antagonist palosuran in cirrhotic rats. Hepatology 2008;47:1264-1276.
9. Trebicka J, Hennenberg M, Laleman W, Shelest N, Biecker E, Schepke M, et al. Atorvastatin lowers portal pressure in cirrhotic rats by inhibition of RhoA/Rhokinase and activation of endothelial nitric oxide synthase. Hepatology 2007;46:242-253.
10. Schepke M, Heller J, Paschke S, Thomas J, Wolff M, Neef M, et al. Contractile hyporesponsiveness of hepatic arteries in humans with cirrhosis: evidence for a receptorspecific mechanism. Hepatology 2001;34:884-888.
11. Bosch J, Garć?a-Pag án JC. Complications of cirrhosis. I. Portal hypertension. J Hepatol 2000;32(suppl 1):141-156.
12. Hennenberg M, Trebicka J, Sauerbruch T, Heller J. Mechanisms of extrahepatic vasodilation in portal hypertension. Gut 2008;57:1300-1314.
13. Zhou Q, Hennenberg M, Trebicka J, Jochem K, Leifeld L, Biecker E, et al. Intrahepatic upregulation of RhoA and Rho-kinase signalling contributes to increased hepatic vascular resistance in rats with secondary biliary cirrhosis. Gut 2006;55:1296-1305.
14. Kuroda S, Tashiro H, Igarashi Y, Tanimoto Y, Nambu J, Oshita A, et al. Rho inhibitor prevents ischemiareperfusion injury in rat steatotic liver. J Hepatol 2012; 56:146-152.
15. Ogawa T, Tashiro H, Miyata Y, Ushitora Y, Fudaba Y, Kobayashi T, et al. Rho-associated kinase inhibitor reduces tumor recurrence after liver transplantation in a rat hepatoma model. Am J Transplant 2007;7:347-355.
16. Etienne-Manneville S, Hall A. Rho GTPases in cell biology. Nature 2002;420:629-635.
17. Sato Y, Murase K, Kato J, Kobune M, Sato T, Kawano Y, et al. Resolution of liver cirrhosis using vitamin A- coupled liposomes to deliver siRNA against a collagenspecific chaperone. Nat Biotechnol 2008;26:431-442.
18. Kikuchi A, Aoki Y, Sugaya S, Serikawa T, Takakuwa K, Tanaka K, et al. Development of novel cationic liposomes for efficient gene transfer into peritoneal disseminated tumor. Hum Gene Ther 1999;10:947-955.
19. Mizunuma K, Ohdan H, Tashiro H, Fudaba Y, Ito H, Asahara T. Prevention of ischemia-reperfusion-induced hepatic microcirculatory disruption by inhibiting stellate cell contraction using rock inhibitor. Transplantation 2003;75:579-586.
20. Elinav E, Ali M, Bruck R, Brazowski E, Phillips A, Shapira Y, et al. Competitive inhibition of leptin signaling results in amelioration of liver fibrosis through modulation of stellate cell function. Hepatology 2009;49:278-286.
21. Sohail MA, Hashmi AZ, Hakim W, Watanabe A, Zipprich A, Groszmann RJ, et al. Adenosine induces loss of actin stress fibers and inhibits contraction in hepatic stellate cells via Rho inhibition. Hepatology 2009;49:185-194.
22. van der Heijden M, Versteilen AM, Sipkema P, van Nieuw Amerongen GP, Musters RJ, Groeneveld AB. Rho-kinasedependent F-actin rearrangement is involved in the inhibition of PI3-kinase/Akt during ischemia-reperfusioninduced endothelial cell apoptosis. Apoptosis 2008;13: 404-412.
23. Anegawa G, Kawanaka H, Yoshida D, Konishi K, Yamaguchi S, Kinjo N, et al. Defective endothelial nitric oxide synthase signaling is mediated by rho-kinase activation in rats with secondary biliary cirrhosis. Hepatology 2008;47:966-977.
24. Takeda K, Jin MB, FujitaM, FukaiM, Sakurai T, Nakayama M, et al. A novel inhibitor of Rho-associated protein kinase, Y-27632, ameliorates hepatic ischemia and reperfusion injury in rats. Surgery 2003;133:197-206.
25. McCuskey RS, Ito Y, Robertson GR, McCuskey MK, Perry M, Farrell GC. Hepatic microvascular dysfunction during evolution of dietary steatohepatitis in mice. Hepatology 2004;40:386-393.
26. El-Badry AM, Moritz W, Contaldo C, Tian Y, Graf R, Clavien PA. Prevention of reperfusion injury and microcirculatory failure in macrosteatotic mouse liver by omega-3 fatty acids. Hepatology 2007;45:855-863.